Efficacy and safety of ultrasound cycloplasty for the treatment of glaucoma: a Meta-analysis

AIM:To evaluate the efficacy and safety of ultrasound cycloplasty(UCP)for glaucoma.METHODS:A comprehensive search of PubMed,Embase,Web of Science,and Google Scholar databases was used to select studies met the inclusion criteria.Metaanalysis was performed by Review Manager and StataCorp LLC.RESULTS:A total of 19 articles met the inclusion criteria.Overall,UCP is effective and safe in the glaucoma treatment,the risk ratio(RR)of the success rate was 2.28(95%CI,1.82-2.84).After UCP,patients had a significant reduction in intraocular pressure(IOP;mm Hg),the weighted mean difference(WMD)was 11.39(95%CI,9.88-12.90).In addition,UCP brings fewer postoperative complications with RR of 0.30(95%CI,0.19-0.49).Most of the complications were short-term and mild.Postoperatively,patients’use of IOP-lowering medications reduced,the standardized mean difference(SMD)was 0.78(95%CI,0.40-1.17).However,best corrected visual acuity(BCVA;logMAR)did not have obvious improvement after UCP,the WMD was 0.01(95%CI,-0.06-0.09).This procedure does provide painfulness relief,with RR of 3.06(95%CI,1.95-4.81).CONCLUSION:UCP is effective and safe for suitable glaucoma.It can effectively decrease IOP in glaucoma patients,reduce the patients’dependence on IOP-lowering medications after surgery,relief the painfulness and has fewer long-term or severe postoperative complications,but the BCVA did not improve much.

Comparison of the efficacy and safety of ultrasonic cycloplasty vs valve implantation and anti-VEGF for the treatment of fundus disease-related neovascular glaucoma

·AIM: To compare the clinical efficacy and safety of ultrasonic cycloplasty(UCP) vs Ahmed glaucoma drainage valve implantation(ADV) in addition to intravitreal antivascular endothelial growth factor(VEGF) for treatment of fundus disease-related neovascular glaucoma(NVG).·METHODS: A total of 43 patients(45 eyes) with NVG secondary to fundus diseases underwent anti-VEGF combined with UCP or ADV from August 2020 to March 2022 were enrolled in this retrospective cohort study. Of them, 14 patients(15 eyes) were treated with both UCP and anti-VEGF as the UCP group and 29 patients(30 eyes) treated with both ADV and anti-VEGF as the ADV group. The success of the treatment was defined as intraocular pressure(IOP) between 11-20 mm Hg with or without using IOP-lowering drugs. IOP measurement, IOP lowering drugs at baseline and follow-ups period and complications were recorded.·RESULTS: The average age was 63.03±9.95 and 52.27±12.89y in ADV and UCP groups, respectively(P=1.947). The fundus pathology included proliferative diabetic retinopathy in 42 eyes and retinal vein occlusion in 3 eyes. All eyes in both groups achieved successful treatment at 3mo. While the success rate was 90.0%(27/30) in the ADV group and 86.7%(13/15) in the UCP group at the last follow-up of 6mo(P>0.05). IOP was significantly lower with reduction of drug use than the baseline in both groups(both P<0.05). And the ADV group needed fewer anti-glaucoma drops than the UCP group from 1d to 3mo. The comfort scores of patients in the ADV group were significantly lower than those in the UCP group in the first week after the operation(P<0.05).·CONCLUSION: UCP is an alternative to the ADV with the same efficacy but non-invasive for the treatment of NVG.

Effect of low dose laser cycloplasty on deepening anterior chamber in chronic angle-closure glaucoma

AIM:To describe the outcome of using low-dose laser cycloplasty(LCP)in chronic angle-closure glaucoma(CACG).METHODS:A retrospective case series.Medical charts of CACG patients who underwent LCP in the Eye Hospital of Wenzhou Medical University were reviewed.The main outcomes included intraocular pressure(IOP),the number of glaucoma medication,anterior segment parameters and surgery-related complications.RESULTS:A total of 7 eyes of 7 CACG patients(age 38.9±11.0y)underwent LCP with a mean follow-up of 27.1±13.7mo(range 16-48mo).Following LCP,mean IOP and glaucoma medications decreased from 26.1±6.1 mm Hg with 3.1±1.1 glaucoma medications pre-treatment to 14.9±3.1 mm Hg(P=0.027)with 0.4±1.1 glaucoma medications(P=0.001)at final follow-up.The anterior chamber depth(ACD),angle opening distance500 and trabecular-iris angle increased from 1.65±0.33 mm,0.05 mm(range 0-0.30 mm)and 5.1°(range,0-31.97°)at baseline to 1.98±0.43 mm(P=0.073),0.53 mm(range 0.42-0.91 mm,P=0.015),45.9°(range,40.2°-59.4°),(P=0.015)in the long-term follow-up,respectively.The deepening of ACD and reopening of anterior chamber angle(ACA)was observed in 6 eyes(85.7%).CONCLUSION:LCP is a promising treatment option for patients with CACG via reducing IOP and glaucoma medication without serious complications.In addition,LCP can bring a significant deepening in ACD and reopening of ACA.